What makes a whisky – and can the process really be accelerated?
New technology may make the question of what makes a whisky a whisky trickier to answer, says Chris Carter


Silicon Valley is the spiritual home of the start-up “accelerator” – programmes that seek to support and advance early-stage companies. A Silicon Valley start-up has now given us the “spirit accelerator”. Earlier this month, Bespoken Spirits, a Californian company founded by materials scientist Martin Janousek and entrepreneur Stu Aaron, unveiled its proprietary technology, which, the company claims, can reproduce the taste of a barrel-aged whisky, rum or brandy in three to five days. The process involves exposing alcohol to “micro staves” of various woods under pressure, not unlike a “Nespresso machine on an industrial scale”. The results have been contested. Bespoken Spirits has won awards in blind tastings. But as Judith Evans notes in the Financial Times, “not all drinkers are convinced”. One reviewer at the Oregon-based Whiskey Wash publication said the bourbon was “not bad”, but that “there was very little that was exciting about this drink either”.
The older way to innovate
That, says the Scotch Whisky Association (SWA), should come as no surprise. Whisky that is sold in Britain and the European Union must be aged for at least three years. “Those quality definitions of whisky as a traditionally aged product, and other spirits produced with other techniques, should be labelled in a way which doesn’t take unfair advantage of that reputation,” the SWA said.
Three years is just the minimum. You can wait much longer and still call your whisky experimental – and the Singleton distillery has done just that. Just over a quarter of a century ago, the distillery’s master of malts, Maureen Robinson, sampled a 12-year-old single malt. She and her team decided to add a second maturation, placing the whisky in a number of experimental casks of used bourbon, Pedro Ximénez oloroso (sherry) seasoned casks and new American oak casks. Then Robinson left it for a while. After 26 more years, the longest second-maturation in the distillery’s history, she deemed it ready. Talk about patience. The Singleton 38-Year-Old has “a thick, creamy texture and a vibrant, sweet start in which rich opening notes of fudge lead smoothly into a lightly spicy, intense and fruity taste suggesting cinnamon-spiced baked apple, drying gently into an autumnal peppery warmth that envelopes the palate”, according to the tasting notes. Just 1,689 will soon be made available, priced at £2,100 (malts.com).
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The rewards of patience
The 38-year-old whisky was “crafted in an era that was very exciting at The Singleton – a time of flavour experimentation and innovation across our whisky-making”, says Robinson. “I remember tasting... samples just three years into the secondary maturation and I was struck how, even at such an early stage, we could identify the richness of flavour the new casks had presented. To mature those casks for more than two decades further was an exploration of how it is possible to unearth exceptional flavour within whisky.” In other words, it pays to take your time when trying new things – even if it does take you 26 years.
Whisky gets a handbagging
Now’s an auspicious time to be bringing out a new whisky. After all, “drinkable investment asset classes have always done well in a downturn, perhaps as their owners have looked to drown their sorrows”, notes Andrew Shirley in the October update of Knight Frank’s The Wealth Report. “Both rare whisky and wine have shown reasonable gains over the past 12 months.” Rare whisky as a collectable asset, in particular, has appreciated by 12% in the 12 months to July. That was the second best of any collectable except for handbags, which have risen by a fifth in value, according to the Knight Frank Luxury Investment Index. Over the decade, whisky is still well out in front of the other sub-indices, with a 535% increase compared with 115% for handbags and 212% for cars, the next biggest grower after whisky over ten years.
But then, you could say the wheels have come off the classic car sector during the pandemic. “The auction market has always provided the razzamatazz for the sector and many sales, including the benchmark autumn Monterey sales [in California], were cancelled or downsized,” says Shirley. That’s not to say there haven’t been any big-ticket sales. A 1934 Bugatti Type 59 Sports set a new record for the marque last month when it sold for £9.5m at Hampton Court Palace. It’s a similar story for the high end of the art market, with the big three auction houses seeing their total sales fall by $2.8bn in the first six months of the year, according to data from ArtTactic. Online sales, at least, have stepped up somewhat, with Francis Bacon’s Triptych Inspired by the Oresteia of Aeschylus (1981 – pictured) selling for $85m in June with Sotheby’s in New York.
Auctions
Going…
One of the world’s great collections of James Bond books is heading for online auction with Sotheby’s in London. An edition of From Russia with Love, inscribed to author Ian Fleming’s wife Ann, carries an estimate of up to £35,000. An edition of Live and Let Die presented to Winston Churchill with the acknowledgement “from whom I stole some words” is valued at up to £70,000. A copy of Diamonds are Forever, which was presented to real-life spy and Bond inspiration Biffy Dunderdale, is expected to fetch up to £20,000. And a first edition of the first Bond book, Casino Royale, from 1953, could make up to £30,000. From next Friday, the books, watches, film posters, and an Aston Martin DB5, are on display at the auction house.
Gone…
Banksy’s Show Me The Monet (2005), a reimagining of Claude Monet’s impressionist water lilies, complete with fly-tipped supermarket trollies and a traffic cone, sold for almost £7.6m at Sotheby’s in London last week. The nine minutes of bidding easily surpassed the £5m upper estimate and the sale price is now the second-highest at auction for a work by the anonymous artist – Devolved Parliament (2009) fetched £9.9m last year. The work forms part of a series by Banksy entitled “Crude Oils”, which “remixes” canonical works. Other pieces in the series include a vase of wilting sunflowers and a take on Edward Hopper’s Nighthawks, featuring an angry man in Union Jack boxer shorts.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Chris Carter spent three glorious years reading English literature on the beautiful Welsh coast at Aberystwyth University. Graduating in 2005, he left for the University of York to specialise in Renaissance literature for his MA, before returning to his native Twickenham, in southwest London. He joined a Richmond-based recruitment company, where he worked with several clients, including the Queen’s bank, Coutts, as well as the super luxury, Dorchester-owned Coworth Park country house hotel, near Ascot in Berkshire.
Then, in 2011, Chris joined MoneyWeek. Initially working as part of the website production team, Chris soon rose to the lofty heights of wealth editor, overseeing MoneyWeek’s Spending It lifestyle section. Chris travels the globe in pursuit of his work, soaking up the local culture and sampling the very finest in cuisine, hotels and resorts for the magazine’s discerning readership. He also enjoys writing his fortnightly page on collectables, delving into the fascinating world of auctions and art, classic cars, coins, watches, wine and whisky investing.
You can follow Chris on Instagram.
-
Tesco braces for supermarket price war with rival Asda
Tesco, Britain’s biggest grocer, has opted to cut its prices more quickly to prevent Asda grabbing market share
By Dr Matthew Partridge
-
Supersonic travel: How China could 'leapfrog' US and Europe's commercial aviation industry
Opinion Innovation in commercial aviation has been stuck for 60 years. A commercial supersonic jet might be back on the market soon, but will China get there first?
By Matthew Lynn
-
BP's 'long, painful decline' – and why next year could be even tougher
Opinion Long-suffering shareholders in oil giant BP have been pushing for change. It won’t come soon enough, says Matthew Lynn
By Matthew Lynn
-
Investment trusts tap the profits in exotic and obscure global markets
Opinion Peter Walls, manager of the Unicorn Mastertrust fund, highlights three investment trusts as he shares where he'd put his money
By Peter Walls
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves